The immunobiological assessment of the antibody titre in treating candidiases by antigens of C. Albicans fungi
Keywords:candidiasis, antigen, vaccine, immunity, therapy, antibody titre
AbstractEvery year candidal infections affect a great number of the population, and annually the number of patients is growing around the world. At the premises of the National University of Pharmacy the authors have developed the method of cell disintegration of Candida albicans fungi. For this purpose ultrasonic disintegration at the wavelength of 22 kHz and exposure of 15 min was used. Then there was filtration through a «Vladipore» membrane MFA-MA No.3 providing separation of the biological material with the size of 10 kDa. The aim of our work was the immunobiological assessment of the antibody titres in treating candidiases with the cell-associated antigens of C. albicans fungi. The immunological action of the cell-associated antigens of C. albicans fungi in treating candidiases was determined in mice. The mice were preliminary infected with the candidal infection. In 5 days after infection the cell-associated antigens of C. albicans fungi under research with the protein concentration of 3 mg/ml in the volume of 0.2 ml were injected intramuscularly to mice twice with an interval of 14 days. Nothing was given to the animals of the control group. In 14 days the protective functions of the animals’ body were determined by the titres of the specific antibodies of C. albicans using enzyme-linked immunoassay (ELISA). When determining the antibody titre after the second injection of the cell-associated antigens of C. albicans fungi it has been found that the antibody titre is in the range of 1:1600 – 4000. The antibody titre in animals of the control group was within 1:400 – 1:1000. Based on the data obtained it may be concluded that the antigens studied have shown the pronounced immunological properties in the experiment in animals.
Голубка О.В. // Annals of Mechnikov Institute. – 2011. – №2. – С. 51-59.
Петров Р.В., Хаитов Р.М. Иммуногены и вакцины нового поколения. – М.: ГЭОСТАР-Медицина, 2011. – 608 с.
Cassone A., Casadevall A. // Curr. Opin. Microbiol. – 2012. – Vol. 15. – P. 1-7.
Carvalho A., Cunha C. // Front. Microbiol. – 2012. – Vol. 3. – P. 1-9.
De Bernardis F. et al. // Vaccine. – 2012. – № 30. – P. 4490-4498.
Diekema D., Arbefeville S., Boyken L. et al. // Diagn. Microbiol. Infect. Dis. – 2012. – №73. – P. 45-48.
Edwards J.E. // Med. Microbiol. – 2012. – №61. – P. 895-903.
Han Y., Rhew K.Y. // Arch. Pharm. Res. – 2012. – №35. – P. 2021-2027.
Copyright (c) 2015 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).